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Abstract
Current evidence suggests that exercise training is beneficial in pulmonary arterial hypertension (PAH). Unfortunately, the standard
supervised, hospital-based programs limit patient accessibility to this important intervention. Our proof-of-concept study aimed to
provide insight into the usefulness of a prescribed walking regimen along with arginine supplementation to improve outcomes for
patients with PAH. Twelve PAH patients (all women) in New York Heart Association (NYHA) functional class (FC) II (n¼ 7) or III
(n¼ 5) and in stable condition for 3 months were enrolled. Patients performed home- and fitness-center- based walking at 65–
75% heart rate (HR) reserve for 45 min, six sessions/week for 12 weeks. Concomitant L-arginine supplementation (6000 mg/day)
was provided to maximize beneficial endothelial training adaptations. Cardiopulmonary exercise testing, 6-min walk testing
(6MWT), echocardiography, laboratory studies, and quality of life (QoL) survey (SF-36) were performed at baseline and 12
weeks. Eleven patients completed the study (72 session adherence rate¼ 96 3%). Objective improvement was demonstrated
by the 6MWT distance (increased by 40 13 m, P¼ 0.01), VO2max (increased by 2 0.7 mL/kg/min, P¼ 0.02), time-to-VO2max
(increased by 2.5 0.6 min, P¼ 0.001), VO2 at anaerobic threshold (increased by 1.3 0.5 mL/kg/min, P¼ 0.04), HR recovery
(reduced by 68 23% in slope, P¼ 0.01), and SF-36 subscales of Physical Functioning and Energy/Fatigue (increased by 70 34%
and 74 34%, respectively, P< 0.05). No adverse events occurred, and right ventricular function and brain natriuretic peptide
levels remained stable, suggesting safety of the intervention. This proof-of-concept study indicates that a simple walking regimen
with arginine supplementation is a safe and efficacious intervention for clinically stable PAH patients, with gains in objective function
and QoL measures. Further investigation in a randomized controlled trial is warranted.
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Until a decade ago, exercise was generally discouraged for
patients with pulmonary arterial hypertension (PAH). Since
then, this opinion has shifted toward a more liberal recom-
mendation in favor of exercise, including a grade 1A rec-
ommendation at the 5th World Symposium on pulmonary
hypertension (PH),1 mainly based on a number of relatively
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small trials that indicated safety of exercise in PAH and
a positive impact on quality of life (QoL) and functional
outcomes.2–16 However, the majority of these trials utilized
hospital-based training programs. In particular, eight stu-
dies included inpatient hospitalization3,5,7,10–12,14,15,17 and
the remainder were performed in a medically supervised out-
patient setting.4,6,9,13,16 Based on this, current treatment
algorithms indicate supervised exercise training;1,18 how-
ever, a more home-based exercise program would be
expected to reduce barriers to referral and adherence, and
be more convenient for many patients, promoting more
widespread use and enhancing compliance.19 A recent
Cochrane systematic review reporting equal eﬀectiveness
of home- vs. center-based cardiac rehabilitation programs
recommended continued expansion of evidence-based,
home-based programs that reﬁect the preference of the
individual patient.20 A customized rehabilitative exercise
program initiated as an independent regimen for patients
with PAH has not been investigated. Our goal was to pro-
vide a proof-of-concept trial for evaluating the eﬀectiveness
of an individually prescribed 12-week home- and ﬁtness-
center-based walking program in patients with mild to mod-
erate PAH. Concomitant L-arginine supplementation was
provided based on the rationale that many patients
with PAH likely experience at least mild systemic or tissue
hypoxia during exercise leading to heightened degradation
of endothelial nitric oxide synthase (eNOS) substrate
L-arginine and potentially blunted vascular endothelial-
mediated adaptations.21–24 Therefore, a commercially avail-
able L-arginine supplement was included in our prescribed
walking regimen, to circumvent this potential limitation and
maximize training eﬀects.
Here we provide proof-of-concept eﬀectiveness of a
simple, mostly home-based walking program plus supple-
mental arginine to improve the primary endpoints of phys-
ical function and QoL without negative training eﬀects
evident on secondary echocardiographic and blood labora-
tory safety endpoints. Some of the results of these studies
have been previously reported in the form of abstracts.25
Methods
This is a prospective pilot interventional study with each
patient serving as his or her control. Patients were recruited
from the Indiana University Pulmonary Hypertension
Clinic (Indianapolis, IN, USA) and additionally at a recruit-
ment booth set up at the 2014 Pulmonary Hypertension
Association International Conference held in Indianapolis,
Indiana. The Indiana University institutional review board
approved the protocol (#1207009162) and all patients gave
written informed consent. The following inclusion criteria
were applied: (1) PAH (World Health Organization
[WHO] Group 1 pulmonary hypertension) established by
right heart catheterization (RHC) within two years prior;
(2) New York Heart Association (NYHA) functional class
(FC) II–III; (3) age 18–75 years; and (4) clinically stable
condition (deﬁned as no changes in treatment for the past
six months and a stable 6-min walking test (6MWT)
(20m) during the previous six months. Exclusion criteria
consisted of the following: NYHA functional class I or IV;
unstable condition; musculoskeletal or other conditions
which would limit exercise participation; non-compliance
with medical therapies; or enrollment in other clinical trials.
The number of patients enrolled was calculated based on a
power of 90% using the primary endpoint of 6MWT, expect-
ing at least a 15% change based on 6MWT improvement
reported with a 15-week exercise training intervention with
a similar population.7 Primary care providers and pulmonol-
ogists were responsible for clinical management of patients.
Exercise training
Walking exercise was performed once/day, six days/week, at
65–75% heart rate (HR) reserve, calculated according to
Karvonen26 using the patients’ resting and peak HR
observed at baseline cardiopulmonary exercise testing
(CPET). Exercise session duration initiated at 25min and
increased to 45min by the end of week 2. Patients were
permitted to choose whether to perform over ground vs.
treadmill walking. For patients that lived in proximity
(<10 miles) to the university (‘‘local individuals,’’ n¼ 7),
two of the six weekly sessions were performed in the
campus ﬁtness center and the remaining four sessions were
performed on their own at home. For patients that did not
live in proximity to the ﬁtness center (‘‘distance individ-
uals,’’ n¼ 5), all six weekly sessions were performed as an
independent home program.
Arginine supplementation
To maximize potentially beneﬁcial endothelial training
adaptations,27–29 patients received a commercially available
L-arginine oral tablet (General Nutrition Centers, Inc.) to
self-administer in three daily doses (6000mg/day)30,31 for 12
weeks, initiated once baseline testing was completed.
Self- and telemonitoring
A HR monitor was provided for use during all exercise ses-
sions and patients were taught how to modulate walking
eﬀort to stay within their target HR zone. While patients
were instructed to use their assigned target HR zone to
guide exercise intensity, they were additionally advised
that rate of perceived exertion (RPE) should not exceed 8
on a 10-point scale and to adjust accordingly as needed.
Patients were also taught to monitor arterial oxygen satur-
ation (SpO2) during exercise with a ﬁngertip pulse oximeter
at ﬁtness center visits. Distance individuals were provided a
take-home ﬁngertip pulse oximeter (Nonin Medical,
Plymouth, MN, USA) for monitoring SpO2 during exercise
since they were unable to be checked weekly with the ﬁtness
center unit. Patients on sildenaﬁl (n¼ 9) were provided
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equipment for daily home blood pressure monitoring. All
patients were provided a logbook to record daily: (1) any
changes in symptoms or self-perceived wellness; (2) minutes
and distance achieved in walking session; (3) RPE during
walking session on a 10-point scale; and (4) self-administra-
tion of daily L-arginine dosing. For local individuals, log-
book entries, HR monitor (Polar Electro, Inc., Woodbury,
NY, USA) data, and overall program tolerance were
reviewed twice weekly at ﬁtness center visits by a trainer.
For distance individuals, these were discussed by telephone
and an additional weekly call was performed.
Endpoints
The following measurements were performed within one
week, before (‘‘Initial’’) and after (‘‘Final’’) the 12-week pro-
gram (Fig. 1): (1) 6MWT to assess distance walked and heart
rate recovery (HRrecovery); (2) CPET; 3) physical examination;
4) Doppler echocardiography; 5) fasting blood laboratories;
and 6) SF-36 standardized survey to assess health-related
QoL. Primary endpoints were change from baseline in
6MWT distance and peak aerobic capacity (VO2max).
Secondary endpoints were change in safety indicators of tri-
cuspid annular plane systolic excursion (TAPSE; a surrogate
of right ventricular [RV] systolic function) on echocardiog-
raphy and plasma concentration of brain natriuretic peptide
(BNP) as an indicator of cardiac wall stress. Adverse events
were deﬁned as hospitalization, death, worsening PH, escal-
ation of therapy, syncope, hypotension, or GI eﬀects.
6MWT distance and heart rate recovery
A 6MWT was performed under standardized conditions32
using an indoor corridor or a gymnasium track. Tester and
testing conditions were kept identical for initial and ﬁnal
testing. HR via continuous measurement with chest strap
(Polar Electro, Inc.) and SpO2 via ﬁngertip oximeter
(Nonin Medical, Plymouth, MN, USA) were recorded pre
test after 5min of quiet sitting. HR and SpO2 were recorded
every minute during 10min of sitting immediately after
6MWT completion. HRrecovery was calculated as the slope
of the relationship between HR and minutes of recovery (0–
10min, as well as just the ﬁrst 5min). HRrecovery is addition-
ally presented as the % of end-exercise (peak) HR at the 10-
min recovery time point.
CPET
CPETs were performed using a continuous, speed- and
incline-incremented maximal treadmill ramp protocol with
2-min stages until volitional fatigue. Ventilation (VE),
oxygen uptake (VO2), and carbon dioxide output (VCO2)
were measured continuously by open-circuit spirometry
using a Vmax by Carefusion Metabolic Measurement
System (BD, Inc., Yorba Linda, CA, USA) and HR was
measured via the 12-lead electrocardiogram. The anaerobic
threshold was detected with the V-slope method. Resting
energy consumption and HR was measured during 5min
of standing on the treadmill before exercise testing. HR
and RPE (using a Borg 6–20-point scale) were recorded in
the middle and last 30 s of each stage.
Step counts
Pedometer-recorded steps walked in one week (including
during exercise sessions) at week 2 and week 11 of the inter-
vention was used to detect any change in overall physical
activity habits. Since there is concern that participants of a
new exercise regimen might choose more sedentary behav-
iors in the non-exercise portion of their days which could
negate some training beneﬁts, the main purpose of collecting
step data was to determine if participants changed their
overall daily physical activity as a consequence of the inter-
vention. All individuals received a pedometer (NL-1000
Accelerometer, New Lifestyles, Inc.) calibrated to his/her
stride to record steps walked for one week at the beginning
of the intervention (week 2) and for one week at the end of
the 12-week period (week 11). Participants were instructed
to wear the pedometer for all out-of-bed non-bathing/swim-
ming activities, including their exercise walking session, for
each seven-day sampling period.
Adherence
Exercise adherence was determined by logbook entries and
conﬁrmed by weekly phone call logs and pedometer data
and is expressed as the percentage of exercise sessions per-
formed out of the 72 prescribed sessions. L-arginine adher-
ence was also determined by logbook entries and conﬁrmed
by weekly phone call logs, as expressed as the percentage
of doses taken out of the 216 doses (3 /day 72 days)
prescribed.
Fig. 1. Study protocol indicating pre- and post-intervention measures, separated by the 12-week walking program.
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Laboratory values
Venous blood sampling was performed pre and post inter-
vention, collected from patients in the sitting position, on
the day of appointment when patient had fasted overnight.
Whole blood samples were immediately sent on ice to the
pathology laboratory of Indiana University Health for pro-
cessing and assays which included: C-reactive protein as an
indicator of systemic inﬂammation; BNP as an indicator of
RV wall stress; a complete blood count (CBC); a standard
metabolic panel and lipid proﬁle; and an amino acid proﬁle
including L-arginine and L-citrulline.
Echocardiography
Doppler echocardiography was used to measure PH param-
eters as recommended by current American Society of
Echocardiography guidelines.33,34M-mode and two-dimen-
sional echocardiography were performed with the patient in
the left lateral position using a General Electric Vivid-q
system (Fairﬁeld, CT, USA). All studies were scanned in
standard views in addition to RV dedicated views when
possible. Tricuspid regurgitant (TR) ﬂow was measured in
continuous wave mode at the parasternal and apical areas
with the highest velocity used for calculation. The peak
instantaneous systolic pressure drop from right ventricle to
atrium (transvalvular gradient) was calculated from the
peak signal velocity of the TR signal by the simpliﬁed
Bernoulli equation. The ﬁnal estimation of pulmonary
artery systolic pressure (PASP) was obtained by adding
the patient’s jugular venous pressure derived from the infer-
ior vena cava size and collapse to the estimate of PASP. RV
diameters were measured at the base in the standard apical
four-chamber view in their respective times in the cardiac
cycle; RA size was measured by planimetry in the apical
four-chamber view at end systole. The presence of a notched
pattern in the pulse wave through the right ventricular out-
ﬂow tract (RVOT) was judged by the cardiology team.
Impaired RV function was measured with: TAPSE mea-
sured using M-mode; and RV fractional area change was
calculated based on the diﬀerence of end-diastolic area and
end-systolic area and divided by end-diastolic area. All stu-
dies were processed in digital format and analyzed using a
digital oﬄine quantiﬁcation system.
Statistical analyses
Paired t-testing measured changes between the pre-test and
post-test in all outcome variables. Analysis of variance
detected diﬀerences between local and distance individuals
in enrollment characteristics, and in baseline and change
values. Data are presented for individuals and as means
with standard error (SEM). Statistical analysis utilized
SPSS v. 23.0 and diﬀerences at a level of 0.05 were con-
sidered statistically signiﬁcant.
Results
Enrollment
A total of 378 patients were screened; 93 had group I PAH
and 12 met the criteria and were enrolled (Fig. 2, Table 1).
Of these, 11 completed the study; the dropout of one patient
was due to time constraints.
Adherence
Adherence to the prescribed exercise regimen was> 95% in
nine participants, and 64% and 94% adherence in the
remaining two participants. Adherence to the prescribed
L-arginine was> 90% in eight individuals and at least
80% adherence in the remaining individuals, except one par-
ticipant who had an adherence of 58%. Weekly average step
count (Table 2) moved in the anticipated direction over the
intervention period with a slight steps-per-week increase
between weeks 2 and 11, expected as pedometer collection
included steps during walking sessions.
Training effects on functional status
6MWT (Fig. 3a, Table 2) distance increased by a mean of
40m. Eight patients (73%) surpassed the minimum clinically
important diﬀerence (MCID) for this population of 33m.35
The slope of HRrecovery (Fig. 3b, Table 2) was improved
(more negative) in all but one participant, with the majority
of improvement occurring within the ﬁrst 5min of recovery.
Faster HRrecovery after training was also evidenced by
patients being at a lower percentage of end-exercise HR at
Fig. 2. Flowchart indicating the number of patients screened for
enrollment, the number of patients and reasons for exclusion, and the
number of patients completed.
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the 10-min recovery time point (Fig. 3c, Table 2). Favorable
changes were also observed in CPET parameters, including
VO2max, time-to-VO2max (Fig. 3d, e, Table 2), and anaer-
obic threshold (AT) (Table 2).
Training effects on quality of life
QoL scores increased by> 70% for SF-36 subscales Physical
Functioning and Energy/Fatigue (Fig. 4a, b, Table 3) with a
tendency for increase in Emotional Wellbeing (P¼ 0.12) and
Role Limitation Physical Health (P¼ 0.19). The Physical
Component Summation (PCS) score, an aggregation of sub-
scales speciﬁc to physical health (Fig. 4c), was also
increased.
No adverse effects of training
No adverse events occurred. Echocardiographic and blood
laboratory data demonstrated that the intervention was not
associated with negative eﬀects (Table 4). In addition to
unchanged BNP, echocardiographic parameters of RV func-
tion such as TAPSE and RV fractional area change also
remained stable over the 12 weeks, suggesting safety of
the intervention. Plasma L-arginine increased markedly
as expected, but no other blood values changed from
baseline.
Outcomes for completely home-based vs. partially fitness-
center-based program
A little less than half of the individuals were distance indi-
viduals and performed all walking sessions independently
at home. While not intended a priori, this provided an
additional opportunity to compare adherence and out-
comes between a partially ﬁtness-center-based vs. com-
pletely home-based program. There was no diﬀerence in
enrollment characteristics (Table 1) or initial values
(Table 2) between these two groups except that the
distance vs. the local individuals tended to be older
(52 5 vs. 37 4 years, P¼ 0.05) with lower initial systolic
blood pressure (101 6 vs. 124 6mmHg, P¼ 0.03) and
higher % age-predicted VO2max (60 5 vs. 44 2% pre-
dicted, P¼ 0.02). There was no diﬀerence in adherence
(93.3 6 vs. 98.3 1%, P¼ 0.47) or pre-post change
values between local and distance individuals for any func-
tional, QoL, echocardiographic, or blood laboratory
outcomes.
Discussion
Our uncontrolled, prospective interventional pilot study
demonstrates that a simple walking program with arginine
supplementation resulted in positive impact on functional
and QoL outcomes for PAH. The improvement is equiva-
lent or better to previously reported more highly structured
training interventions conducted in a medically supervised
setting. In addition, no adverse events occurred and echo-
cardiographic and blood indicators of RV function and wall
stress remained stable over the 12-week period, suggesting
safety of this mostly home-based intervention in a PAH
patient cohort.
Improvements in functional status
Compared to that reported for trials of supervised cycling or
treadmill exercise in PH, similar or greater gains were
attained in 6MWT distance2–6,9,10,12,13,16,36 and VO2max or
Table 1. Participant characteristics at enrollment.
Age (years) 44 4.0
Gender (n)
Women 12
Men 0
Height (cm) 160 1.0
Weight (kg) 79 6.8
BMI 30 2.8
6MWD (m) 482 17
PAH etiology (n)
Idiopathic 8
Connective tissue disease 1
Congenital heart disease 3
NYHA class (n)
II 6
III 6
Co-morbidities (n)
Hypertension 3
Diabetes mellitus 1
Hyperlipidemia 3
Obstructive sleep apnea 3
Oxygen use (n) 2
PAH therapy (n)
Prostacyclin 4
Caþchannel blocker 2
ERA 2
PDE5 inhibitor 9
Hemodynamics
mPAP (mmHg) 44 5
PAWP (mmHg) 12 2
PVR (WU) 6.6 1.5
Cardiac index (mL/min/m2) 3.1 0.3
Chart values obtained at time of enrollment for the 12 enrolled
patients are presented as n, or as means SEM where indicated.
BMI, body mass index; 6MWD, 6-min walk distance; PAH, pul-
monary arterial hypertension; NYHA, New York Heart
Association; ERA, endothelin receptor antagonist; PDE,
phosphodiesterase; mPAP, mean pulmonary arterial pressure;
PAWP, pulmonary arterial wedge pressure; PVR, pulmonary vas-
cular resistance.
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time to VO2max
3–7,12–14,16,36 following our mostly home-
based walking program. Improvement in 6MWT and/or
VO2max was also as good or better than those reported in
exercise trials that included add-ons such as respira-
tory2,5,7,11,12,14,36 or resistance2–7,10–12,14,36 training. Of the
patients, 73% surpassed the 6MWT distance MCID for
PAH (33m),35 as well as for chronic obstructive pulmonary
disease (COPD) and heart failure (54–55m),37 with a mean
improvement of almost twice the MCID. Improved aerobic
ﬁtness was also evidenced by a higher VO2 at AT and faster
HRrecovery, a parameter that has not been customarily
reported in exercise trials for PAH but has been proposed
to be an important marker predictive of clinical worsening
and time to clinical worsening in patients with idiopathic
PAH.38 A possible association of autonomic dysfunction
with survival in PAH39–41 makes the improvement observed
in HRrecovery after our simple walking program even more
relevant and important.
Improvements in quality of life
Patient gain in QoL was as good as or better than that
reported for exercise trials in PH that have included patient
counseling or mental training/coaching sessions.5,7,10,12–14,36
However, we cannot rule out that even further gains in QoL
or functional indicators would have occurred if such add-
itional components had been included in the 12-week
program.
Adherence and feasibility
While adherence to prescribed exercise for patients with
PAH is only reported for a limited number of trials to
date, the 96 3% adherence rate for our 72-session walking
program was as good as4 or better3,12,13,16 compared to that
in trials utilizing more highly structured interventions that
report adherence rates. The close verbal communication
Table 2. Change in hemodynamics, weekly step count, 6MWT, and CPET.
Variable Initial Final Absolute change P value Change (%)
Weight (kg) 79 7 79 7 –0.2 0.7 0.81 0.0 0.9
Resting HR (bpm) 83 3 79 3 –4.0 3.7 0.32 –3.7 4.6
Systolic BP (mmHg) 113 5 113 5 –0.1 4.6 0.98 0.7 3.9
Diastolic BP (mmHg) 81 5 75 3 –6.8 5.9 0.27 –5.6 5.3
Pedometer 1-week average (steps/day) 7717 809 8276 917 559 522 0.31 3.8 6.9
6MWT
Distance (m) 481 18 521 23 40 13.4* 0.01 8.6 2.6
Peak HR (bpm) 112 4 126 8 14 4.0* 0.01 7.7 4.8
HRrecovery (slope 0–5 min) –4 0.5 –7 3 –2.7 0.8** 0.008 65.0 22
HRrecovery (slope 0–10 min) –2 0.3 –3 0.4 –1.2 0.4* 0.01 68.0 19
HRrecovery (%peak HR at 10 min) 80 2.4 68 2.7 –12 2.5** 0.001 –14.2 3
CPET
Time to VO2max (min) 9.5 0.6 12.0 1.1 2.5 0.6** 0.001 24.4 4.9
VO2max (mL/kg/min) 15.7 1.2 17.5 1.1 1.8 0.7* 0.02 13.2 4.7
VO2max (L/min) 1.2 0.1 1.3 0.1 0.13 0.1* 0.02 12.7 4.3
VO2max %predicted 51.4 3.7 58.1 3.8 6.6 2.5* 0.03 13.7 5.0
Ventilation max (L/min) 45.8 4.7 49.7 5.6 6.0 3.2 0.11 13.0 6.0
Peak METs 5.3 0.4 5.4 0.3 0.2 0.2 0.38 5.0 3.6
HR at rest (bpm) 93 6 89 4 –4.9 4.8 0.33 –3.3 4.8
HRmax (bpm) 155 6 152 4 –2.5 3.0 0.49 –1.1 2.3
Borg scale at max 16.5 0.5 15.2 1.3 –1.1 1.1 0.36 –7.2 7.5
VO2 at AT (mL/kg/min) 13.4 1.5 14.4 1.2 1.3 0.5* 0.047 9.9 4.3
SBP (mmHg) / VO2 (mL/kg/min) 3.7 0.6 3.4 0.6 –0.2 0.5 0.76 13.0 6.0
VE/VCO2 mid 38.2 0.4 36.4 0.3 –1.3 1.2 0.31 5.0 3.6
65–75% HRreserve 133-9 7 130-6 7 –3.2 3 0.40 –1.8 2.6
Values are means SEM for the 11 of 12 patients that completed the study. Paired t-testing was used to analyze changes between the pre-test (Initial) and post-test
(Final) at the end of 12 weeks in all outcome variables, with bold type and asterisks indicating a significant change (*P< 0.05 and **P< 0.01) in comparison to
baseline.
HR, heart rate; bpm, beats per minute; BP, blood pressure; 6MWT, 6-min walk test; VO2max, maximum oxygen consumption; MET, metabolic equivalent; Peak HR,
highest HR achieved; HRrecovery, HR relative to minutes of recovery; AT, anaerobic threshold; SBP, change in systolic blood pressure from rest to peak exercise;
VO2, change in VO2 from rest to peak exercise; VE/VCO2, ventilatory equivalent for carbon dioxide; 65–75%HRreserve, calculated according to formula of
Karvonen.26
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with patients and the tools provided (HR monitors, training
logs, pedometers) may have contributed to our exceptionally
high adherence. Weekly average step count remained con-
sistent between week 2 and week 11 indicating that out-
comes were not confounded by large swings in the
sedentary or physical activity habits of patients over this
time. Since pedometer recordings included exercise sessions,
the slight steps-per-week increase observed may be
accounted for by walking speed increases with patient con-
ditioning as expected, but the methodology precludes this
assessment.
Adherence was equally good for local vs. distance indi-
viduals, suggesting that this is not dependent on in-person
interaction between patient and trainer. The high exercise
adherence of our trial not only reduced risk of patients not
being dosed as intended with the intervention,42,43 but also
suggests that this approach may have favorable patient
compliance when implemented in practice. Indeed, the
ﬁnancial and logistical burden on patients, clinicians, care-
givers, and third-party payers, was quite low for our inter-
vention especially compared to training approaches
previously investigated for PAH that encompassed inpatient
hospitalization and issue of a cycle ergometer for each
patient upon discharge.7 For example, the cost per patient
for our 12-week exercise intervention was under US$800
and no work hours were missed for employed patients to
participate. Though exercise trials for PH conducted in an
outpatient setting4,6,9,13,16 have a clear feasibility advantage
by not requiring an inpatient component, these too can pre-
sent signiﬁcant challenges to implementation and compli-
ance44,45 such as transportation and location46,47 and long
wait periods for availability.46 These are eliminated with
home-based exercise programs. Further, due to newer and
more available technologies (e.g. wearable accelerometers,
Fig. 3. Training improvements in aerobic exercise tolerance and cardiorespiratory fitness. Individual responses are presented as different
colored lines from initial to final values for 11 patients who completed the study. Paired t-testing was used to analyze changes between the pre-
test (Initial) and post-test at the end of 12 weeks (Final) in all outcome variables. Mean SEM and P values for pre- to post-intervention change
are presented in bar graphs adjacent to individual responses. (a) 6MWT distance for n¼ 11; (b) HRrecovery as slope of relationship between HR
and 0–10 min of recovery following 6MWT for n¼ 10 (missed collection in one participant), including an additional bar graph indicating
mean SEM for slope of relationship between HR and 0–5 min of recovery; (c) HRrecovery % of end-6MWT HR at the 10-min recovery time point
for n¼ 10 (missed collection in one individual); (d) maximal rate of oxygen consumption relative to kg of body mass (VO2max) in CPET for n¼ 10
(unable to collect expired gases in one participant that required supplemental oxygen during exercise); (e) number of minutes completed of CPET
incremental treadmill protocol for n¼ 11.
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pulse oximeters, personalized web-based exercise tracking
and coaching applications) home-based programs now
have much more feedback and interaction with patients;
this may enhance preference, compliance, safety, and eﬀect-
iveness.48,49 Feasibility of home-based exercise interventions
has been demonstrated for patients with COPD,50 myocar-
dial infarction,51,52 and heart failure,53 and our results sug-
gest feasibility for patients with PAH as well.
Concomitant arginine supplementation
This study provides initial insight into usefulness of con-
comitant L-arginine for patients participating in an exercise
regimen, on the basis that positive training eﬀects may be
augmented by provision of increased substrate for eNOS,
thus increasing nitric oxide bioavailability in the pulmonary
vasculature.27,29,54–56 Plasma L-arginine was eﬀectively
increased by the supplementation provided and our ﬁndings
agree with a previous report of VO2max improvement with
L-arginine supplementation in pre-capillary PH.28 However,
our small proof-of-concept study design precludes evalu-
ation of L-arginine’s speciﬁc impact on endpoints.
Nonetheless, it is possible that some of the functional
gains observed were augmented by L-arginine attenuating
pulmonary pressure rise relative to workload, which is a
known exercise limiter for this population.57,58 While this
pilot study was not powered or designed to test adherence
and tolerance to L-arginine, both were observed to be good
across all patients and no patients experienced gastrointes-
tinal distress, hypotension, or other adverse symptoms.
Further placebo-controlled studies examining the impact
of this readily available and inexpensive supplement, or
other potential enhancers of endothelial-mediated positive
exercise responses in PAH, are warranted, as has been
demonstrated with L-arginine plus training for cardiac and
skeletal muscle of healthy trained rats29,54 and pulmonary
arteries of pulmonary hypertensive rats.27
Limitations
This proof-of-concept study was intended to merely pilot
feasibility for use of a mostly home-based training approach
plus arginine supplementation. As such, there was no con-
trol comparative group for the walking intervention and
each participant served as their own control. Further, as
discussed above, this small feasibility study included no
group receiving L-arginine only or exercise only, with the
intention that these variables be examined independently in
a subsequent larger controlled trial.
Fig. 4. Training improvements in QoL as assessed by the SF-36.
Individual responses are presented as different colored lines from ini-
tial to final values for 11 patients who completed the study. Paired t-
testing was used to analyze changes between the pre-test (Initial) and
post-test at the end of 12 weeks (Final) in all outcome variables.
Mean SEM and P values for pre- to post-intervention change is
presented in bar graphs adjacent to individual responses. (a) SF-36
subscale for Physical Function; (b) SF-36 subscale for Energy/Fatigue;
and (c) SF-36 Physical Component Summation (PCS) score.
Table 3. Quality of life.
SF-36 Scale Initial Final
Absolute
change P value
Change
(%)
Physical functioning 58 8 79 7 21 8* 0.03 70 34
Energy/Fatigue 48 7 66 4 17 6* 0.02 74 34
Role limitations due
to physical health
75 12 91 6 16 11 0.19 53 37
Bodily pain 81 5 83 5 2 2 0.29 3 2
General health
perception
53 4 55 7 2 5 0.68 4 11
Social functioning 76 7 78 6 2 8 0.79 14 16
Role limitations due
to emotional
97 3 91 6 0 0 0.34 0 0
Emotional wellbeing 72 5 83 3 11 6 0.12 28 19
Values are means SEM for the 11 of 12 patients that completed the study.
Paired t-testing was used to analyze changes between the pre-test (Initial) and
post-test (Final) at the end of 12 weeks in all SF-36 quality of life scales, with
bold type and asterisks indicating a significant change (*P< 0.05) in comparison
to baseline.
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The enrollment number was small and the presence of a
selection bias toward more motivated and higher function-
ing patients is likely, supported by slightly higher 6MWT
distances at baseline than is typical for a PAH population.59
It is possible that observations reported here following train-
ing may have been aﬀected diﬀerently in a cohort with more
impairment at baseline. For instance, improvement in
6MWT may have been even greater if we had enrolled a
more functionally limited patient cohort.60 On the other
hand, more impaired individuals may have resulted in
lower adherence due to greater diﬃculty completing the
protocol.
Since exclusion criteria included non-compliance with
medical therapies, it is possible that examining a low-
structure intervention approach that speciﬁcally aims to
remove barriers to compliance as we have done here may
Table 4. Change blood laboratory and echocardiography parameters (n¼ 11).
Initial Final Absolute change P value Change (%)
Blood laboratory
WBC 7.71 0.7 7.42 0.6 –0.3 0.5 0.57 –2.1 5.2
Hemoglobin (g/dL) 13.60 0.4 13.45 0.4 –0.2 0.2 0.57 1 1.9
Platelets 250.36 25.6 266.18 27.3 15.8 11.5 0.20 6.8 4.7
Sodium (mmol/L) 138.18 0.7 137.45 0.7 –0.7 0.6 0.27 –0.5 0.5
Bicarbonate (mmol/L) 23.20 1.2 24.27 0.9 0.9 0.5 0.12 4.7 2.5
Creatinine (mg/dL) 0.84 0.1 0.82 0.1 –0.01 0.01 0.34 –1.3 1.6
BNP (pg/mL) 109.82 58.1 96.00 44.2 –13.8 17.9 0.46 16.4 25
L-arginine (nmol/mL) 48.82 4.4 81.82 10.7 33.0 9.6* 0.006 72.1 18
L-citrulline (nmol/mL) 31.91 3.7 37.36 4.7 5.5 3.8 0.19 19.9 11.3
Insulin sensitivity (TG/HDL) 2.82 0.4 2.52 0.2 –0.3 0.2 0.29 –1.7 10.3
C-reactive protein (mg/L) 5.63 1.9 5.32 1.4 –0.3 0.9 0.74 43.7 26.2
Echocardiography
RA area 17.62 2.1 18.92 1.8 1.3 1.3 0.35 11.2 8.6
Estimated RA pressure 7.10 0.8 6.60 0.9 –0.5 0.9 0.59 4.2 19.8
TR jet gradient 38.04 4.6 41.06 6.9 3.0 3.6 0.43 5.7 9.1
TAPSE 1.57 0.2 1.56 0.1 –0.01 0.1 0.93 4 8.2
RV EDD 4.14 0.3 4.19 0.2 0.05 0.1 0.76 2.6 4
RV ESD 3.38 0.3 3.40 0.2 0.020 0.1 0.90 2.5 4.1
RV FS 0.19 0.0 0.19 0.0 0.001 0.03 1.0 23.8 27.4
RV EDA 27.35 2.4 28.39 2.5 1.04 1.4 0.47 4.7 5.2
RV ESA 19.20 2.9 19.21 2.9 0.007 1.06 0.99 2.1 5.7
RV FA change 0.32 0.0 0.34 0.0 0.02 0.03 0.43 11.6 10.8
L atrial AP diameter 3.16 0.1 3.15 0.1 –0.01 0.1 0.92 0.5 3
LV EDD 4.31 0.2 4.05 0.3 –0.3 0.2 0.25 –6.2 5.5
LV ESD 2.82 0.2 2.72 0.2 –0.1 0.1 0.60 –1.3 7.3
LV FS 34.95 3.1 31.86 3.2 –3.1 3.7 0.43 –4.3 9.9
LV EDV 93.03 8.6 92.39 6.3 –3.4 9.1 0.72 0.7 9.8
LV ESV 34.23 4.9 42.01 4.4 2.9 5.0 0.58 18.5 16.5
LV EF 64.22 2.8 58.62 1.8 –4.8 2.1 0.07 –7.1 3.3
LV SV 61.38 4.8 52.75 3.0 –9.4 5.1 0.11 –11.6 7.4
AVA 2.70 0.1 2.84 0.3 0.30 0.4 0.68 10.2 7.4
E/A 1.28 0.1 1.15 0.1 –0.13 0.09 0.20 –7.2 7
E/E’ 8.01 0.7 7.80 0.6 –0.27 1.6 0.84 3.8 12.4
Values are means SEM for the 11 of 12 patients that completed the study. Paired t-testing was used to analyze changes between the pre-test
(Initial) and post-test (Final) at the end of 12 weeks in all outcome variables, with bold type and asterisks indicating a significant change (*P< 0.05) in
comparison to baseline.
WBC, white blood cell count; BNP, brain natriuretic peptide; TG, triclycerides; HDL, high-density lipoprotein; RA, right atrial; TR, tricuspid
regurgitant; TAPSE, tricuspid annular plane systolic excursion; RV, right ventricle; LV, left ventricle; EDD, end-diastolic diameter, ESD, end-systolic
diameter; FS, fractional shortening; EDA, end-diastolic area; ESA, end-systolic area; FA change, fractional area change; AP, anteroposterior; EDV, end-
diastolic volume; ESV, end-systolic volume; EF, ejection fraction; SV, stroke volume; AVA, aortic valve area; E/A, average ratio of transmitral Doppler E
wave velocity to A wave velocity; E/E’, ratio of Doppler-derived peak E velocity and early diastolic E’ velocity at mitral annulus.
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not have contributed as much to the outcomes as it would
for less compliant patients. Also, regarding compliance,
there is inherent weakness in relying primarily on self-
report for exercise adherence which was the case for 10
out of the 12 weeks of the intervention, since pedometer
counts were only collected during weeks 2 and 11. A subse-
quent trial would be strengthened with the inclusion of
devices such as wearable accelerometer activity monitors
to measure daily adherence to the exercise intervention.
Lastly, screening of 110 patients was required to enroll 12
patients, and ﬁve of these patients lived too far away to
conveniently utilize the ﬁtness center, therefore performing
all their walking sessions on their own at home. Comparable
outcomes for these patients suggests that a completely
home-based program is as eﬃcacious as a partially ﬁtness-
center-based program; however, the study was not ade-
quately powered a priori to make meaningful comparisons
in outcomes between these two groups.
In conclusion, our mostly home-based prescribed walking
regimen plus arginine supplementation for clinically stable
PAH patients elicited good adherence and gains in function
and QoL on par with those reported for more highly struc-
tured exercise interventions. The proof-of-concept feasibility
demonstrated here supports the need for a subsequent ran-
domized clinical trial to further investigate this potentially
paradigm-changing approach to exercise prescription for
PAH.
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